When combined with a growing body of evidence that patient-specific eQTLs in the GRAF3 gene are associated with human hypertension [19,47,48,49], these studies suggest that GRAF3 might be an attractive target for the treatment of HTN. This evidence concerns the gene ARHGAP42 and Hypertension.